

NeuTec Pharma plc

NeuTec Pharma plc (“NeuTec” or the “Company”) Result of EGM and AGM

16 August 2004 At the Extraordinary General Meeting of the Company held at 10.00 a.m. on 16 August 2004 and the Annual General Meeting held immediately thereafter, all of the resolutions proposed at each meeting were approved.

Accordingly, it is expected that admission of the Open Offer Shares to trading on AIM will become effective and that dealings will commence on AIM at 8.00 a.m. on 20 August 2004.

Enquiries:

NeuTec Pharma plc	www.neutecpharma.com
Professor James Burnie, CEO	0161 276 8827
Andrew King, Finance Director	07771 867 890

Hoare Govett Limited	020 7678 8000
Andrew Foster	
Sean Wegerhoff	

Financial Dynamics	020 7831 3113
Ben Atwell	
Lucy Briggs	

Definitions used in the *NeuTec* prospectus dated 23 July 2004 shall have the same meaning when used in this announcement, unless the context requires otherwise.

Hoare Govett Limited, which is regulated in the United Kingdom by the Financial Services Authority, is acting as nominated adviser and broker to the Company in relation to the Placing and Open Offer, and is not responsible to any other person for providing the protections afforded to clients of Hoare Govett Limited or for providing advice in relation to the Placing and Open Offer, the contents of this announcement or any other matter referred to herein. Hoare Govett Limited’s responsibilities as nominated adviser and broker are owed solely to the London Stock Exchange and are not owed to the Company or to any Director or to any other person in respect of their decision to acquire Open Offer Shares in reliance on any part of this announcement. No representation or warranty, express or implied, is made by Hoare Govett Limited as to any of the contents of this announcement.